| Open |
S1937 |
A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for,… |
2/16/2021 |
|
33% |
|
|
| Closed |
SWOG-8809 |
A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE- MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas |
10/1/1988 |
11/15/1994 |
100% |
|
Published
|
| Open |
S2312 |
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature |
9/3/2024 |
|
0% |
|
|
| Closed |
SWOG-9420 |
A Phase III Trial of Continuous Low-Dose Infusion versus Intermittent High-Dose Infusion of 5-Fluorouracil in Patients with Disseminated Colorectal Cancer |
4/15/1995 |
5/15/1999 |
100% |
|
Published
|
| Open |
S2213 |
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab… |
12/1/2023 |
|
1% |
|
|
| Closed |
SWOG-8907 |
A Phase ll Trial of Combination Chemotherapy Plus Verapamil in Drug Refractory Intermediate Grade and Selected High Grade Non-Hodgkin's Lymphomas |
7/1/1989 |
12/15/1991 |
46% |
|
Published
|
| Closed |
SWOG-8712 |
A Phase ll Trial of Trimetrexate in the Treatment of Hepatoma |
7/15/1987 |
1/1/1989 |
|
|
Published
|
| Closed |
SWOG-9418 |
A Pilot Study Evaluating an Educational Program to Increase Utilization of Cervical and Breast Cancer Screening Methods in Hispanic Women |
5/1/1994 |
1/1/1996 |
|
|
Published
|
| Closed |
SWOG-9060 |
A Pilot Study Evaluation of Multimodality Treatment of Local Regional Esophageal Carcinoma, Phase II |
11/1/1991 |
3/1/1993 |
100% |
|
Published
|
| Closed |
SWOG-9019 |
A Pilot Study of Chemotherapy Plus Radiation Therapy for Selected IIIb (No Malignant Effusion) Non-Small Cell Lung Cancer |
4/15/1992 |
12/1/1995 |
100% |
|
Published
|
| Closed |
SWOG-9024 |
A Pilot Study of Combined Modality Therapy in T3, 4; N0, M0 Adenocarcinoma of the Prostate, Phase II |
8/1/1991 |
3/15/1995 |
62% |
|
Published
|
| Open |
S1933 |
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status |
6/15/2020 |
|
83% |
|
|
| Closed |
SWOG-8706 |
A Prospective Study of Three Post-Remission Therapies in Adult Acute Nonlymphocytic Leukemia: Allogeneic Transplantation vs. Autologous Transplantation vs. Consolidation Chemotherapy |
4/1/1988 |
12/15/1990 |
23% |
|
Published
|
| Closed |
SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12) |
A Randomized Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy, Versus Radiation Therapy Alone in Selected Patients with Stages I-A2, I-B and II-A Carcinoma of the… |
9/1/1990 |
12/15/1996 |
100% |
|
Published
|
| Closed |
SWOG-8600 |
A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia |
11/1/1986 |
12/1/1991 |
99% |
|
Published
|
| Open |
S2000 |
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases |
9/23/2020 |
|
100% |
|
|
| Closed |
S1900F |
A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib In Patients With Non-Squamous RET Positive Stage IV NSCLC and Progression of Disease On Prior RET Directed Therapy |
7/25/2022 |
6/27/2023 |
0% |
|
|
| Closed |
SWOG-9349 |
A Randomized Phase II Trial of CHOP with G-CSF Support or ProMACE-CytaBOM with G-CSF Support for Treatment of Non-Hodgkin's Lymphoma |
9/15/1994 |
1/15/1997 |
100% |
|
Published
|
| Open |
MM1YA-S01 |
A Randomized Phase II Trial of Novel Agents in Adults with Acute Myeloid Leukemia |
5/16/2024 |
|
1% |
|
|
| Open |
S1914 |
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC |
3/25/2020 |
|
87% |
|
|
